The 2024 ESMO annual meeting included a session on prostate cancer, featuring a discussion presentation by Dr. Niven Mehra discussing three abstracts including “Efficacy and safety of darolutamide plus ADT in patients with mHSPC from the phase 3 ARANOTE trial” by Dr. Fred Saad, “Prostate cancer efficacy results from a randomized phase 3 evaluation of transdermal …

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

4 days ago · February 3, 2025 The AMBASSADOR trial represents a landmark advancement in the treatment paradigm for muscle-invasive urothelial carcinoma (MIUC), particularly for patients with high-risk MIUC following radical surgery. 1 In our recent editorial featured as Spotlight of Cell Reports Medicine, we delve into the critical findings of the AMBASSADOR trial and their …

About UroToday-GU Oncology Today ® UroToday - GU Oncology Today brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.This site presents content on critical areas of research and clinical practice, providing researchers and clinicians the opportunity to evaluate original research, case studies, peer …

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Published 13 September 2024 (UroToday.com) The 2024 ESMO annual meeting included a session on expanding bladder preservation by optimal use of systemic therapy and biomarkers, featuring a presentation by Dr. Leslie Ballas discussing whether clinical responders have an option for chemoradiation.

Jan 30, 2025 · Gut Microbiota-Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling. January 31, 2025 Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways. January 31, 2025 Prostate Artery Embolization in ...

Oct 17, 2024 · ESMO 2024, metastatic castration resistant prostate cancer (mCRPC), SPLASH trial,177Lu-PSMA-617, PSMAfore trial, 177Lu-PNT2002, enzalutamide, abiraterone, VISION trial, androgen receptor pathway inhibitor (ARPI).

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO GU 2024 Bladder Cancer. ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery; ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)